Trials / Withdrawn
WithdrawnNCT03730779
Oxygen Therapy for Retinal Ischemia
Normobaric Nocturnal Hyperoxia Therapy for Treating Ischemic-Related Retinal Conditions
- Status
- Withdrawn
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Beth Israel Deaconess Medical Center · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The investigators will be using nocturnal normobaric hyperoxia therapy in patients with diagnoses of conditions related to retinal ischemia.
Detailed description
Patients who receive a diagnosis of a condition relate to retinal ischemia and who pass the eligibility criteria will receive an oxygen concentrator to use at home. They will report back in follow up monthly for three to six months.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Hyperoxia | Patients will receive nocturnal normobaric hyperoxia therapy |
Timeline
- Start date
- 2018-11-30
- Primary completion
- 2020-01-01
- Completion
- 2020-01-01
- First posted
- 2018-11-05
- Last updated
- 2020-03-09
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03730779. Inclusion in this directory is not an endorsement.